• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process

    Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time

    Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC).

    Neal C. Bradsher, Founder and President of Broadwood, said:

    "For more than three months, we have been telling the Board of Directors that its decision to sell STAAR to Alcon came at the wrong time, resulted from the wrong process, and was at the wrong price. The vast majority of shareholders and all three major proxy advisory firms shared our perspective and overwhelmingly opposed this misbegotten transaction.

    We are pleased that the Board now recognizes – albeit belatedly – the flaws in its initial process, including with respect to timing, and acknowledges the benefits of a wider solicitation of proposals. However, as we have pointed out for months, ‘window shops' and ‘go-shops' are never good substitutes for a well-designed, well-timed, thorough sale process.

    One thing we are certain of: shareholders will have little confidence in the outcome of this ‘go-shop' if the same directors, bankers, and lawyers who designed and executed an inappropriate and flawed sale process in the first place remain in exclusive control of these new palliative measures.

    As STAAR's largest shareholder, we have been asking for weeks for the Board to engage in dialogue with shareholders and for changes to the Board so that truly independent directors could assist in the evaluation of the best path forward. This Board has confounded us and our fellow shareholders with its myriad, and apparently conflict-ridden, decisions and lack of transparency, including about other strategic interest in the Company. Given these missteps, and the lack of sufficient public company sale experience on the Board, having new directors to ensure there are no further false starts, delays, misrepresentations, or mistakes is more critical than ever in our view.

    We understand that the founder of one of STAAR's largest shareholders, Yunqi Capital, has expressed an interest in serving on the Board. And we remain willing to identify other qualified and independent candidates for the Board, including candidates who have experience overseeing well-managed sale processes and have a strong understanding of directors' fiduciary duties to shareholders.

    The Board should have some humility. It repeatedly and vociferously recommended the Alcon deal, which was roundly and overwhelmingly rejected by shareholders and proxy advisory firms alike. In a continuing scramble to salvage its ill-conceived deal, the Board has now delayed the shareholder vote three separate times. Dare we say, the problem lies with the Board, not with the shareholders; all the delays and patches and band-aids just underscore that point.

    As the Board can surely appreciate, we have lost confidence in the Board's ability to make good and objective decisions on our behalf. The right, humble, and necessary response is for this Board to embrace accountability and sound governance by augmenting its membership with new directors whom investors can trust. Absent such a responsible move, we believe shareholders will doubt the outcome of this appended go-shop ‘fix-er-up' process, and the credibility of the Board will be even further damaged in the eyes of shareholders."

    Shareholders can find additional information at www.LetSTAARShine.com.

    About Broadwood

    Broadwood Partners, L.P. is managed by Broadwood Capital, Inc. Broadwood Capital is a private investment firm based in New York City. Neal Bradsher is the President of Broadwood Capital.

    Certain Information Concerning the Participants

    Special Meeting of Shareholders Scheduled for October 23, 2025

    Broadwood Partners, L.P., Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn, Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the "Participants") are participants in the solicitation of proxies from the shareholders of STAAR in connection with the special meeting of shareholders scheduled for October 23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the "Special Meeting"). The Participants have filed a definitive proxy statement on Schedule 14A (the "Definitive Proxy Statement") and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies from the Company's shareholders for the Special Meeting. SHAREHOLDERS OF STAAR ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE "SEC") BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The Definitive Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of STAAR's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

    Special Meeting of Shareholders to Remove Members of the Board

    The Participants also intend to file a definitive proxy statement and an accompanying GREEN Proxy Card with the SEC to be used to solicit proxies with respect to removing members of the Board and any other proposals that may come before a future and yet to be called or otherwise scheduled special meeting of shareholders (including any adjournments, postponements, reschedulings or continuations thereof, the "Shareholder Meeting"). The Shareholder Meeting will be separate, distinct and unrelated to the Special Meeting, and the Participants believe that the Shareholder Meeting will have no effect on the outcome of the Special Meeting. The Participants do not believe that there is any lawful reason that would prevent or prohibit the Participants from calling the Shareholder Meeting, regardless of the outcome of the shareholder vote at the Special Meeting, and do not make any representation related to whether the Company may contest, or otherwise challenge, the Participants' ability to call the Shareholder Meeting. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SHAREHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some or all of the Company's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

    Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on October 22, 2025 and is available here.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251110498145/en/

    Investor Contacts

    John Ferguson / Joseph Mills

    Saratoga Proxy Consulting LLC

    jferguson@saratogaproxy.com

    jmills@saratogaproxy.com

    (212) 257-1311

    (888) 368-0379

    Media Contacts

    Scott Deveau / Jeremy Jacobs

    August Strategic Communications

    Broadwood@AugustCo.com

    (323) 892-5562

    Get the next $ALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC
    $STAA

    CompanyDatePrice TargetRatingAnalyst
    STAAR Surgical Company
    $STAA
    5/14/2026$40.00Neutral → Outperform
    Wedbush
    STAAR Surgical Company
    $STAA
    4/9/2026$27.00Hold → Buy
    Canaccord Genuity
    Alcon Inc.
    $ALC
    2/26/2026$97.00Equal Weight → Overweight
    Wells Fargo
    STAAR Surgical Company
    $STAA
    2/3/2026$26.00Neutral
    Wedbush
    Alcon Inc.
    $ALC
    1/30/2026Mkt Perform
    William Blair
    Alcon Inc.
    $ALC
    1/20/2026Hold → Buy
    Deutsche Bank
    STAAR Surgical Company
    $STAA
    1/16/2026$13.00Underweight
    Morgan Stanley
    Alcon Inc.
    $ALC
    1/9/2026Buy → Hold
    Stifel
    More analyst ratings

    $ALC
    $STAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    STAAR Surgical Announces Participation in Upcoming Investor Conferences

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026 Format: Meetings and Webcast Fireside Chat Details: Investor meeting participation is by invitation only from the sponsoring brokerage firm. Webcast: 4:30 PM ET, Webcast Link Canaccord Genuity Virtual Fireside Chat Date: Wednesday, May 27, 2026 Format: Webcast Fireside Chat Details: Registration for the webcast is by invitation only via the sponsoring brokerage firm. Webcast: 2:3

    5/21/26 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter

    Net Sales of $93.5 million, highest first quarter Net Sales in Company's history, up 119.6% Y/Y Net Income of $5.2 million, with GAAP EPS of $0.10 Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended April 3, 2026. First Quarter 2026 Financial Overview Net sales of $93.5 million, up 119.6% Y/Y Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $

    5/13/26 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    New Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds

    First-quarter 2026 sales of $2.7 billion, up 10% on a reported basis, or up 6% constant currency1 (cc), versus first-quarter 2025 First-quarter 2026 diluted EPS of $0.39; core diluted EPS2 of $0.85 Dividend of 0.28 CHF per share approved at AGM Announced new $1.5 billion share repurchase authorization over 3 years Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31, 2026. For the first quarter of 2026, sales were $2.7 billion, up 10% on a reported basis and up 6% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported dilu

    5/5/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Development Officer Michna Magda was granted 19,795 shares and covered exercise/tax liability with 9,703 shares, increasing direct ownership by 31% to 42,783 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    5/19/26 4:01:03 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Interim Co-CEO and CFO Andrews Deborah J was granted 15,699 shares and covered exercise/tax liability with 5,632 shares (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    5/19/26 4:01:05 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Interim Co-CEO and Pres. & COO Foust Warren covered exercise/tax liability with 16,785 shares and was granted 32,990 shares, increasing direct ownership by 24% to 83,112 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    5/19/26 4:01:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ALC
    $STAA
    SEC Filings

    View All

    $ALC
    $STAA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    STAAR Surgical upgraded by Wedbush with a new price target

    Wedbush upgraded STAAR Surgical from Neutral to Outperform and set a new price target of $40.00

    5/14/26 8:02:15 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded STAAR Surgical from Hold to Buy and set a new price target of $27.00

    4/9/26 8:23:39 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Alcon from Equal Weight to Overweight and set a new price target of $97.00

    2/26/26 7:10:22 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SD filed by Alcon Inc.

    SD - ALCON INC (0001167379) (Filer)

    5/15/26 11:12:17 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by STAAR Surgical Company

    10-Q - STAAR SURGICAL CO (0000718937) (Filer)

    5/13/26 4:06:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - STAAR SURGICAL CO (0000718937) (Filer)

    5/13/26 4:02:18 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Director Broadwood Partners, L.P. bought $12,266,545 worth of shares (670,213 units at $18.30) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/13/26 7:59:59 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $606,138 worth of shares (27,485 units at $22.05) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    1/13/26 9:30:12 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $8,817,664 worth of shares (406,653 units at $21.68) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    1/8/26 7:31:31 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Leadership Updates

    Live Leadership Updates

    View All

    STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

    Search Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the "Board") has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work together with the other members of the executive leadership team, with support and guidance from the Board, as they lead the Company and manage its day-to-day operations.

    2/2/26 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

    Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital have Joined STAAR Board STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have Stepped Down from the Board Farrell will Remain CEO until January 31, 2026 STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates ("Broadwood"), which together own 31% of STAAR's outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5%

    1/15/26 8:30:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Financials

    Live finance-specific insights

    View All

    STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter

    Net Sales of $93.5 million, highest first quarter Net Sales in Company's history, up 119.6% Y/Y Net Income of $5.2 million, with GAAP EPS of $0.10 Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended April 3, 2026. First Quarter 2026 Financial Overview Net sales of $93.5 million, up 119.6% Y/Y Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $

    5/13/26 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    New Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds

    First-quarter 2026 sales of $2.7 billion, up 10% on a reported basis, or up 6% constant currency1 (cc), versus first-quarter 2025 First-quarter 2026 diluted EPS of $0.39; core diluted EPS2 of $0.85 Dividend of 0.28 CHF per share approved at AGM Announced new $1.5 billion share repurchase authorization over 3 years Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31, 2026. For the first quarter of 2026, sales were $2.7 billion, up 10% on a reported basis and up 6% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported dilu

    5/5/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Announces Results of 2026 Annual General Meeting

    Shareholders approve all agenda items presented R. Scott Herren elected as new independent member of the Board 2025 Compensation Report and Report on Non-Financial Matters approved in consultative votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2026 Annual General Meeting ("AGM"). A total of 283,222,421 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 11,328,896.84, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the

    4/30/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    9/6/24 9:51:09 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/13/24 5:14:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by Alcon Inc.

    SC 13G - ALCON INC (0001167379) (Subject)

    2/13/24 3:47:46 PM ET
    $ALC
    Ophthalmic Goods
    Health Care